【摘要】 目的探讨DNA切除修复交叉互补组1(ERCC1)蛋白在非小细胞肺癌(NSCLC)中的表达与临床预后的关系。方法采用免疫组织化学Envision法检测90例NSCLC组织中ERCC1表达。结果 NSCLC组织ERCC1总阳性率为45.55%(41/90),与癌旁组织比较的差异有统计学意义(P<0.003)。ERCC1表达及强度与患者年龄、性别、肿瘤大小、组织学类型、淋巴结转移和临床分期无明显关系(P>0.05)。临床Ⅱ期以上ERCC1阳性表达者生存率低于阴性表达者(P=0.004)。临床Ⅰ期ERCC1阳性表达者生存率高于阴性表达者,但差异无统计学意义。结论 ERCC1蛋白表达可作为临床Ⅱ期以上NSCLC患者预后的评估指标。更多还原

【Abstract】 Objective To investigate the relationship between the expression and clinical prognosis of(excision repair cross-complementation group 1)ERCC1 in patients with non-small cell lung cancer(NSCLC).Methods Expression levels of ERCC1 was detected with the Envision method of immunohistochemistry.Results The general positive expression rates for ERCC1 was 45.55%(41/90) in NSCLC tissues,and was significantly higher than that in adjacent normal lung tissues(P<0.003).The expression and expression levels of ERCC1 had no relationship with the age,sex,tumor size,histological type,lymph node metastases and clinical stages(P>0.05).In clinical stageⅠ,the survival rates of patients with positive expression of ERCC1 was higher than that of negative and there was no significant difference.In the other stages,the survival rates of patients with positive expression of ERCC1 were lower than that of negative(P=0.004).Conclusion ERCC1 expression in NSCLC tissue are an independent prognostic factors for patients with clinical stageⅡ,Ⅲ and Ⅳ.更多还原